FR1525186A
(fr)
|
1967-03-29 |
1968-05-17 |
Roussel Uclaf |
Nouvelles pénicillines et procédé de préparation
|
EP0028489B1
(en)
|
1979-11-05 |
1983-10-05 |
Beecham Group Plc |
Enzyme derivatives, and their preparation
|
DE4034829A1
(de)
|
1990-11-02 |
1992-05-07 |
Merck Patent Gmbh |
Cyclopeptide
|
JP3190431B2
(ja)
|
1991-07-01 |
2001-07-23 |
三菱化学株式会社 |
ケトン誘導体
|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
WO1996034010A2
(en)
|
1995-03-29 |
1996-10-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5624936A
(en)
|
1995-03-29 |
1997-04-29 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000507597A
(ja)
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシルタンパク質トランスフェラーゼ阻害剤
|
PE121699A1
(es)
|
1997-02-18 |
1999-12-08 |
Boehringer Ingelheim Pharma |
Heterociclos biciclicos disustituidos como inhibidores de la trombina
|
ZA985247B
(en)
|
1997-06-19 |
1999-12-17 |
Du Pont Merck Pharma |
Guanidine mimics as factor Xa inhibitors.
|
WO2000077027A2
(en)
|
1999-06-14 |
2000-12-21 |
Tularik Limited |
Serine protease inhibitors
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
KR100898094B1
(ko)
|
1998-03-19 |
2009-05-18 |
버텍스 파마슈티칼스 인코포레이티드 |
카스파제의 억제제
|
IL139599A0
(en)
|
1998-05-26 |
2002-02-10 |
Warner Lambert Co |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
US6307049B1
(en)
|
1998-09-30 |
2001-10-23 |
The Procter & Gamble Co. |
Heterocyclic 2-substituted ketoamides
|
BR9916732A
(pt)
|
1999-01-02 |
2001-09-25 |
Aventis Pharma Gmbh |
Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
|
EP1016663A1
(en)
|
1999-01-02 |
2000-07-05 |
Aventis Pharma Deutschland GmbH |
Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
|
DE50008510D1
(de)
|
1999-04-09 |
2004-12-09 |
Abbott Gmbh & Co Kg |
Niedermolekulare inhibitoren von komplementproteasen
|
DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
EP1125925A1
(en)
|
2000-02-15 |
2001-08-22 |
Applied Research Systems ARS Holding N.V. |
Amine derivatives for the treatment of apoptosis
|
AU5959201A
(en)
|
2000-05-11 |
2001-11-20 |
Bristol Myers Squibb Co |
Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
AR035216A1
(es)
|
2000-12-01 |
2004-05-05 |
Astrazeneca Ab |
Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
|
AU2002322802A1
(en)
|
2001-07-27 |
2003-02-17 |
Merck And Co., Inc. |
Thrombin inhibitors
|
US6951840B2
(en)
|
2001-08-31 |
2005-10-04 |
Eli Lilly And Company |
Lipoglycopeptide antibiotics
|
CN110894196A
(zh)
|
2001-09-21 |
2020-03-20 |
百时美-施贵宝控股爱尔兰无限公司 |
含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
|
US6649606B1
(en)
|
2001-11-09 |
2003-11-18 |
Bristol-Myers Squibb Co. |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
AU2002316317A1
(en)
|
2002-06-18 |
2003-12-31 |
The Scripps Research Institute |
Synthesis of diazonamide "a" core
|
US20040180855A1
(en)
|
2003-02-19 |
2004-09-16 |
Schumacher William A. |
Methods of treating thrombosis with reduced risk of increased bleeding times
|
US7138412B2
(en)
|
2003-03-11 |
2006-11-21 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives useful as serine protease inhibitors
|
US7129264B2
(en)
|
2003-04-16 |
2006-10-31 |
Bristol-Myers Squibb Company |
Biarylmethyl indolines and indoles as antithromboembolic agents
|
AU2004263508A1
(en)
|
2003-08-08 |
2005-02-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions, and methods of use
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
US7429604B2
(en)
|
2004-06-15 |
2008-09-30 |
Bristol Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
JP2008505976A
(ja)
|
2004-07-12 |
2008-02-28 |
アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド |
テトラペプチド類似体
|
WO2006076575A2
(en)
|
2005-01-13 |
2006-07-20 |
Bristol-Myers Squibb Company |
Substituted biaryl compounds as factor xia inhibitors
|
WO2006089005A2
(en)
|
2005-02-17 |
2006-08-24 |
Bristol-Myers Squibb Company |
Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
|
WO2007047608A2
(en)
|
2005-10-14 |
2007-04-26 |
Epix Pharmaceuticals, Inc. |
Fibrin targeted therapeutics
|
KR20080067697A
(ko)
|
2005-11-11 |
2008-07-21 |
에프. 호프만-라 로슈 아게 |
응고 인자 xa의 억제제로서 카보사이클릭 융합된사이클릭 아민
|
WO2007070816A2
(en)
|
2005-12-14 |
2007-06-21 |
Bristol-Myers Squibb Company |
Thiophene derivatives as factor xia inhibitors
|
WO2007070818A1
(en)
|
2005-12-14 |
2007-06-21 |
Bristol-Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
AR058379A1
(es)
|
2005-12-14 |
2008-01-30 |
Bristol Myers Squibb Co |
Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
|
AR058380A1
(es)
|
2005-12-23 |
2008-01-30 |
Bristol Myers Squibb Co |
Inhibidores del factor viia macrociclicos utiles como anticoagulantes
|
JP5342450B2
(ja)
|
2006-12-15 |
2013-11-13 |
ブリストル−マイヤーズ スクイブ カンパニー |
第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
|
PE20081775A1
(es)
|
2006-12-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
AU2008266228A1
(en)
|
2007-06-13 |
2008-12-24 |
Bristol-Myers Squibb Company |
Dipeptide analogs as coagulation factor inhibitors
|
US8324199B2
(en)
|
2008-03-13 |
2012-12-04 |
Bristol-Myers Squibb Company |
Pyridazine derivatives as factor xia inhibitors
|
US8624040B2
(en)
|
2009-06-22 |
2014-01-07 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
US8513433B2
(en)
|
2009-07-02 |
2013-08-20 |
Angion Biomedica Corp. |
Small molecule inhibitors of PARP activity
|
US8609676B2
(en)
|
2009-08-04 |
2013-12-17 |
Merck Sharp & Dohme, Corp. |
4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
|
JP5844287B2
(ja)
*
|
2010-02-11 |
2016-01-13 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
第xia因子阻害剤としてのマクロ環
|
US9161924B2
(en)
|
2011-07-08 |
2015-10-20 |
Merck Sharp & Dohme Corp. |
Factor IXa inhibitors
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
TW201319068A
(zh)
*
|
2011-08-05 |
2013-05-16 |
必治妥美雅史谷比公司 |
作為xia因子抑制劑之環狀p1接合劑
|
CA2851810C
(en)
|
2011-10-14 |
2020-01-07 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
US9079929B2
(en)
|
2011-10-14 |
2015-07-14 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
|
EP2899183B1
(en)
|
2011-10-14 |
2018-09-19 |
Bristol-Myers Squibb Company |
Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
|
BR112014015669B1
(pt)
|
2011-12-21 |
2021-10-13 |
Ono Pharmaceutical Co., Ltd |
Compostos derivados de piridinona e pirimidinona, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para o tratamento ou prevenção de uma doença tromboembólica
|
GB2497806A
(en)
|
2011-12-21 |
2013-06-26 |
Ono Pharmaceutical Co |
Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
|
EP2807156A1
(en)
|
2012-01-27 |
2014-12-03 |
Novartis AG |
Aminopyridine derivatives as plasma kallikrein inhibitors
|
EP2807157A1
(en)
|
2012-01-27 |
2014-12-03 |
Novartis AG |
5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
|
JP2015083542A
(ja)
|
2012-02-08 |
2015-04-30 |
大日本住友製薬株式会社 |
3位置換プロリン誘導体
|
JP6348900B2
(ja)
|
2012-05-10 |
2018-06-27 |
バイエル ファーマ アクチエンゲゼルシャフト |
凝固因子xiおよび/またはその活性化形態である因子xiaに結合しうる抗体ならびにその用途
|
GB201209138D0
(en)
|
2012-05-24 |
2012-07-04 |
Ono Pharmaceutical Co |
Compounds
|
AU2013291098A1
(en)
|
2012-07-19 |
2015-02-05 |
Sumitomo Dainippon Pharma Co., Ltd. |
1-(cycloalkyl-carbonyl)proline derivative
|
CN104507924B
(zh)
*
|
2012-08-03 |
2018-01-23 |
百时美施贵宝公司 |
二氢吡啶酮p1作为凝血因子xia抑制剂
|
KR20150038369A
(ko)
*
|
2012-08-03 |
2015-04-08 |
브리스톨-마이어스 스큅 컴퍼니 |
인자 XIa 억제제로서의 디히드로피리돈 P1
|
MX351848B
(es)
|
2012-10-12 |
2017-10-31 |
Bristol Myers Squibb Co |
Formas cristalinas de inhibidor del factor xia.
|
US9403774B2
(en)
|
2012-10-12 |
2016-08-02 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
EP2906552B1
(en)
|
2012-10-12 |
2017-11-22 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
US9708308B2
(en)
|
2012-12-19 |
2017-07-18 |
Merck Sharp Dohme Corp. |
Factor IXa inhibitors
|
GB201300304D0
(en)
|
2013-01-08 |
2013-02-20 |
Kalvista Pharmaceuticals Ltd |
Benzylamine derivatives
|
GB2510407A
(en)
|
2013-02-04 |
2014-08-06 |
Kalvista Pharmaceuticals Ltd |
Aqueous suspensions of kallikrein inhibitors for parenteral administration
|
JP6479763B2
(ja)
|
2013-03-25 |
2019-03-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
第xia因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
|
TWI633089B
(zh)
|
2013-03-28 |
2018-08-21 |
拜耳製藥股份有限公司 |
經取代的酮基吡啶衍生物
|
US9475809B2
(en)
|
2013-07-23 |
2016-10-25 |
Bayer Pharma Aktiengesellschaft |
Substituted oxopyridine derivatives and use thereof as factor xia/plasma
|
AR097755A1
(es)
|
2013-09-26 |
2016-04-13 |
Bayer Pharma AG |
Derivados sustituidos de fenilalanina como moduladores del factor xia
|
WO2015044170A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
|
US20160280699A1
(en)
|
2013-09-26 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
US20160272617A1
(en)
|
2013-09-26 |
2016-09-22 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
EP3049408A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
TW201605828A
(zh)
|
2013-09-26 |
2016-02-16 |
拜耳製藥股份有限公司 |
經取代苯丙胺酸衍生物(三)
|
US20160244437A1
(en)
|
2013-09-26 |
2016-08-25 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
EP3049410A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate als faktor xia modulatoren
|
US20160229839A1
(en)
|
2013-09-27 |
2016-08-11 |
Merck Sharp & Dohme Corp. |
Factor XIa Inhibitors
|
EP3054944B1
(en)
|
2013-10-07 |
2019-12-04 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
JP6337750B2
(ja)
|
2013-11-22 |
2018-06-06 |
小野薬品工業株式会社 |
化合物
|
EP3095786A4
(en)
|
2014-01-14 |
2017-10-11 |
Sumitomo Dainippon Pharma Co., Ltd. |
Condensed 5-oxazolidinone derivative
|
NO2760821T3
(US07585860-20090908-C00136.png)
|
2014-01-31 |
2018-03-10 |
|
|
WO2015116886A1
(en)
|
2014-01-31 |
2015-08-06 |
Bristol-Myers Squibb Company |
Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
|
KR101927114B1
(ko)
|
2014-02-07 |
2018-12-10 |
엑시테라 파마슈티컬스 인코퍼레이티드 |
치료 화합물 및 조성물
|
EP3104701B1
(en)
|
2014-02-11 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
US9944643B2
(en)
|
2014-02-11 |
2018-04-17 |
Merck Sharp & Dohme Corp. |
Factor XIa inhibitors
|
EP3104702B1
(en)
|
2014-02-11 |
2022-08-10 |
Merck Sharp & Dohme LLC |
Factor xia inhibitors
|
EP3138839B1
(en)
|
2014-02-14 |
2020-10-28 |
Sichuan Haisco Pharmaceutical Co., Ltd. |
Pyridone or pyrimidone derivative, preparation method therefor and application thereof
|
HUE052668T2
(hu)
|
2014-03-07 |
2021-05-28 |
Biocryst Pharm Inc |
Trifluorometillel szubsztituált pirazolok mint humán plazma kallikrein-gátlók
|
WO2015160636A1
(en)
|
2014-04-16 |
2015-10-22 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
EP3131896B1
(en)
|
2014-04-16 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
KR20150136294A
(ko)
|
2014-05-27 |
2015-12-07 |
주식회사 레고켐 바이오사이언스 |
인자 XIa 억제 활성을 가지는 신규한 화합물
|
KR20170005871A
(ko)
|
2014-05-28 |
2017-01-16 |
머크 샤프 앤드 돔 코포레이션 |
인자 XIa 억제제
|
EP3197891B1
(de)
|
2014-09-24 |
2018-11-21 |
Bayer Pharma Aktiengesellschaft |
Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
|
NO2721243T3
(US07585860-20090908-C00136.png)
|
2014-10-01 |
2018-10-20 |
|
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
TWI696620B
(zh)
|
2014-12-10 |
2020-06-21 |
日商小野藥品工業股份有限公司 |
二氫吲酮衍生物
|
WO2016205482A1
(en)
|
2015-06-19 |
2016-12-22 |
Bristol-Myers Squibb Company |
Diamide macrocycles as factor xia inhibitors
|